Patients
NSCLC, tumor, lower bile duct cancer, intrahepatic cholangiocarcinoma
TUMOR, SOLID TUMORS, SOLID TUMOR, NONSMALL CELL LUNG CANCER, INTRAHEPATIC CHOLANGIOCARCINOMA, NSCLC, ONCOLOGY, DISEASE CHARACTERISTIC
A total of 44 patients with advanced solid tumors were enrolled at 10 study centers in Japan: 14 in Part 1 (dose escalation) and 30 in Part 2 (dose expansion). Patients received pemigatinib 9, 13.5, or 18 mg on an ID regimen in Part 1 and pemigatinib 13.5 mg on ID or CD in Part 2 (Figure Summary of patient disposition. QD, once daily.Patients were predominantly male (61.4%), with median age of 63 and most (75.0%) had an ECOG PS of 0 (Table Baseline demographics and disease characteristics.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FGF, fibroblast growth factor; FGFR, FGF receptor; NSCLC, nonsmall cell lung cancer.Four patients were categorized as having a tumor type of “other: intrahepatic cholangiocarcinoma” and 1 was categorized as having lower bile duct cancer. These five patients were included in the “other solid tumor” category.Seven patients enrolled in Part 2 did not have 